Lv5
1230 积分 2022-08-19 加入
Measurable residual disease‐driven treatment in first‐line chronic lymphocytic leukaemia
29天前
已完结
Treatment of Relapsed/Refractory MCL
29天前
已完结
A manganese-oxide nano-rambutan as the intrinsic modifier for hypericin delivery and triple-negative breast cancer treatment
1个月前
已完结
Product-Specific Impact of Viscosity Modulating Formulation Excipients During Ultra-High Concentration Biotherapeutics Drug Product Development
1个月前
已完结
USFDA-approved parenteral peptide formulations and excipients: Industrial perspective
1个月前
已完结
Predicting the Long-Term Stability of Biologics with Short-Term Data
1个月前
已完结
Flow Activation Energy of High-Concentration Monoclonal Antibody Solutions and Protein–Protein Interactions Influenced by NaCl and Sucrose
1个月前
已完结
An industry perspective on hyaluronidase co-formulated biopharmaceutics
1个月前
已完结
Dismantling relapsed/refractory mantle cell lymphoma
2个月前
已完结
皖公网安备34019202002308
